PERSONALIS INC (PSNL)
US71535D1063 - Common Stock
Personalis to Announce First Quarter 2024 Financial Results
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
Personalis to Participate at Upcoming Investor Conferences
Personalis and ClearNote Health enter into a partnership (NASDAQ:PSNL)
Personalis forms an alliance with ClearNote to expand its pharmaceutical services, bringing a real-time monitoring platform for cancer therapies.
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Personalis forecasts upbeat Q4 revenue outlook (NASDAQ:PSNL)
Personalis (PSNL) exceeds Q4 revenue expectations with $19.7M, while projecting higher full-year 2023 revenue of $73.5M.
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
Friday Sector Laggards: Biotechnology, Rubber & Plastics
Personalis files for $200M mixed shelf (NASDAQ:PSNL)
Financial writer reports Personalis files a prospectus for a mixed shelf offering of up to $200M, clarifying it's not an offer to sell securities.
Personalis expects workforce reduction to extend cash runway into 2026 (NASDAQ:PSNL)
Cancer test developer, Personalis, expects extended cash runway into 2026 after eliminating 65 jobs, boosting shareholder confidence with a 4.1% increase in...
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
Cancer test developer Personalis to cut 65 jobs to reduce costs (NASDAQ:PSNL)
Personalis, a cancer test developer, announced a reduction in workforce of up to 65 employees to cut costs, resulting in $14 million in savings by 2024.
Personalis stock slips after deal with Tempus (NASDAQ:PSNL)
Tempus Labs to receive 9.2M Personalis (PSNL) shares from a partnership to co-commercialize the latter's NeXT Personal Dx cancer detection test. Read more here.
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing